Abstract
<h3>Objectives</h3> To integrate the data published on the effect of teriparatide (TPTD) therapy on cases of medication-related osteonecrosis of the jaw (MRONJ) in a comprehensive analysis of clinical features. <h3>Study Design</h3> An electronic search was undertaken in 6 databases. Descriptive analyses of clinicodemographic data of MRONJ were carried out. Poisson regression was also run to evaluate predictors of total resolution of MRONJ treated with TPTD. <h3>Results</h3> Twenty-six publications comprising 143 cases were included. Most reported cases affected women (82.0%), with a mean age of 76.54 years. Osteoporosis represented the main reason for using antiresorptive drugs (76.5%), with bisphosphonates (98.1%) as the most frequently reported. The mandible was the most affected site (75.8%), with a mean evolution time of 5 months. Regarding TPTD treatment, in 45.1% of cases, TPTD was used alone, with total resolution observed in 59.5% of individuals. Poisson regression demonstrated that individuals with MRONJ stage 1 were 1.218 times more likely to present total resolution of osteonecrosis than individuals with MRONJ stage 3 (95% CI, 1.027-1.438; <i>P</i> < .023). <h3>Conclusions</h3> TPTD in combination with another therapy should be considered an effective therapeutic modality for MRONJ.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
